7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with carboplatin in 1 studies
| Studies (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Trials (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Recent Studies (post-2010) (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 39 | 15 | 14 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F | 1 |
1 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and carboplatin
| Article | Year |
|---|---|
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2009 |